Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

MedMira Inc V.MIR

Alternate Symbol(s):  MMIRF

MedMira Inc. is a Canada-based developer and manufacturer of Rapid Vertical Flow (RVF) diagnostics. The Company's tests provide hospitals, labs, clinics and individuals with instant disease diagnosis, such as human immunodeficiency virus (HIV), syphilis, hepatitis, and SARS-CoV-2, in three steps. The Company is engaged in the business of research, development and manufacturing of rapid diagnostics and technologies. Its research is focused on specific areas of the broader diagnostics market, namely the rapid, point-of-care, and in vitro sectors. Its tests are sold globally under the REVEAL, REVEALCOVID-19, Multiplo and Miriad brands. Based on its patented Rapid Vertical Flow Technology, the Company's rapid HIV test has regulatory approvals in Canada, the United States, China and the European Union. Its manufacturing facilities are located in Halifax, Nova Scotia, Canada. It provides access to its RVF Technology for researchers, developers, and biotech companies on a license basis.


TSXV:MIR - Post by User

<< Previous
Bullboard Posts
Next >>
Post by red2000on Jan 26, 2021 1:00pm
102 Views
Post# 32388409

Intellectual property

Intellectual propertyFrom Sedar.com
Management’s Discussion & Analysis For the year ended July 31, 2020 

Intellectual property The Company strives to protect its intellectual property in established and emerging markets around the world as warranted.

MedMira’s intellectual property portfolio for its Rapid Vertical Flow Technology and the methodology behind its rapid diagnostics includes the following:

Patent # Title Jurisdiction
9,164,087 Rapid Diagnostic Device, assay and multifunctional Buffer United States
9,086,410 Downward or vertical flow diagnostic device and assay United States
8,025,850 Rapid Diagnostic Device, Assay and Multifunctional Buffer United States
3 8,287,817 Rapid Diagnostic Device, Assay and Multifunctional Buffer United States
8,586,375 Rapid Diagnostic Device, Assay and Multifunctional Buffer United States
7,531,362 Rapid Diagnostic Device, Assay and Multifunctional Buffer United States
D706945 Diagnostic Device United States D706466 Diagnostic Device United States EP1417489 Rapid Diagnostic Device and Assay Europe
ZL02819646.5 Rapid Diagnostic Device and Assay China
2,493,616 Rapid Diagnostic Device, Assay and Multifunctional Buffer Canada

The Company has other patents pending patents in the U.S. as well as two design patents in force or pending in eight markets.

The Company’s corporate and product brand names are protected by trademarks in the U.S. and Canada
<< Previous
Bullboard Posts
Next >>